Research programme: antibody targeted amanitin conjugates - Heidelberg Pharma

Drug Profile

Research programme: antibody targeted amanitin conjugates - Heidelberg Pharma

Alternative Names: anti-CD19-amanitin conjugate; anti-CD269-amanitin conjugate; ATACs - Heidelberg Pharma/Roche; BCMA-amanitin conjugate; CD 19 - ATAC; HDP-101; HDP-101-ATAC

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator Heidelberg Pharma
  • Developer Heidelberg Pharma; WILEX AG
  • Class Drug conjugates; Immunotoxins
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Multiple myeloma; Solid tumours

Most Recent Events

  • 05 Apr 2017 Pharmacokinetics and pharmacodynamics data from a preclinical study in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 25 Jan 2017 Heidelberg Pharma signs license agreement covering B-cell maturation antigen antibodies (BCMA) from Max Delbrück Center for Molecular Medicine
  • 13 Oct 2016 Heidelberg Pharma plans a clinical trial for Solid tumours in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top